Nyrada (ASX:NYR) ROCE %: -119.85% (As of Dec. 2025)


ASX:NYR Nyrada Inc ASX:NYR
25 GF Score
Price A$0.43
! 1 Warning Sign
View Full Analysis

What is Nyrada ROCE %?

Nyrada ASX:NYR +4.88% 25 ROCE % is -119.85% as of Dec. 2025. GuruFocus rates ASX:NYR with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nyrada's annualized ROCE % for the quarter that ended in Dec. 2025 was -119.85%.

Nyrada  (ASX:NYR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nyrada ROCE % Related Terms

Nyrada ROCE % Historical Data

* Premium members only.

The historical data trend for Nyrada's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada ROCE % Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -36.19 -30.41 -118.31 -102.52 -171.17

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -104.50 -102.29 -122.84 -170.77 -119.85
ASX:NYR
25GF Score
Nyrada Inc ASX:NYR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada ROCE % Calculation

Nyrada's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-7.404/( ( (5.907 - 0.836) + (5.3 - 1.72) )/ 2 )
=-7.404/( (5.071+3.58)/ 2 )
=-7.404/4.3255
=-171.17 %

Nyrada's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-8.046/( ( (5.3 - 1.72) + (10.393 - 0.546) )/ 2 )
=-8.046/( ( 3.58 + 9.847 )/ 2 )
=-8.046/6.7135
=-119.85 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -119.85% mean?
Nyrada (ASX:NYR) has a ROCE % of -119.85% as of Dec. 2025.
Is Nyrada's ROCE % too high?
Nyrada's current ROCE % is -119.85%. Overall, Nyrada has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's ROCE % compare to VRTX and REGN?
Nyrada's ROCE % of -119.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Nyrada's current ROCE % is -119.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current ROCE % of -119.85%. The current ROCE % is -119.85%. Nyrada's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current ROCE % is -119.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
25GF Score

Get the complete analysis for ASX:NYR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.43
Price